NGS growth Phalanx Biotech Group expanded its offerings in 2017 to include Next Generation Sequencing services and corresponding bioinformatics, presenting an opportunity to cross-sell sequencing workflows, data analysis, and validation services to existing microarray and expression profiling customers.

Expression profiling With OneArray microarrays for whole-genome, microRNA, and custom targets, there is potential to upsell complementary sequencing-based expression analysis, validation services, and custom assay development to academic and biotech customers pursuing comprehensive transcriptomic projects.

Biomarker opportunities The combination of genomics research products and NGS services positions Phalanx to target pharma and biotech clients developing biomarkers, companion diagnostics, or precision medicine programs requiring integrated genomics workflows and validation.

Mid-market focus Revenue in the low to mid single-digit millions with a 11-50 employee base indicates a nimble, relationship-driven sales approach. There is an opportunity to scale by offering tiered service packages, managed services, and strategic collaborations with mid-sized life science companies.

Global service model Serving academic, pharmaceutical, and biotech communities worldwide suggests a preparedness to onboard international partners, form strategic reseller or coopetition agreements, and tailor language, regulatory, and bioinformatics support to diverse markets.